Dry (Atrophic) Macular Degeneration
Discover unique market-leading data and insights into the Dry (Atrophic) Macular Degeneration market. From the latest Dry (Atrophic) Macular Degeneration industry reports and analysis to comprehensive market growth forecasts, trends and research.
Browse our full list of Dry (Atrophic) Macular Degeneration market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Product Insights Dry (Atrophic) Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Dry (Atrophic) Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$2,500 | March 2024 Dry (Atrophic) Macular Degeneration Clinical Trials Market Report Overview There were a total of 145 dry (atrophic) macular degeneration clinical trials conducted as of March 2024. The dry (atrophic) macular degeneration clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials...
-
Product Insights
Product Insights Dry (Atrophic) Macular Degeneration – Drugs In Development, 2023 Dry (Atrophic) Macular Degeneration – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Dry (Atrophic) Macular Degeneration - Drugs In Development, 2023’, provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.